Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glucosil is a proprietary silver-chitosan antimicrobial technology developed by Chitosan Health. It is designed as a platform for coating or embedding within medical textiles (such as scrubs, linens, and privacy curtains) and medical devices (including catheters and silicone-based components) to prevent healthcare-associated infections. The technology combines the antimicrobial properties of silver ions with chitosan, a natural biopolymer. Chitosan's positive charge attracts negatively charged pathogens, while silver ions facilitate their destruction and the penetration of protective biofilms. Glucosil has demonstrated preclinical efficacy against a range of high-priority pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), Clostridioides difficile, Candida auris, and Pseudomonas aeruginosa, without promoting significant bacterial resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Glucosil.